Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gilead Maintains Optimistic Outlook For Yescarta Despite Slow Growth

Executive Summary

Gilead projects roughly $200m in sales growth for its CAR-T product Yescarta, despite the drug’s modest $6m sequential growth during the fourth quarter. For 2019 overall sales, the company projects slight growth, if any.


Related Content

Galapagos Targets Liver Fibrosis With Evotec Deal
Q4 Pharma Earnings Preview: Roche, Celgene, Novo Nordisk, Merck, Gilead
The Case For CAR-T Grows As Responses Hold Up Longer Term
Gilead Lures Roche Pharma CEO O'Day As CEO; Genentech's CEO Will Replace Him
Gilead’s Yescarta Growth Continues, But Momentum Slowed
New Data Cast Doubt On Gilead's Phase III NASH Candidate Selonsertib
Gilead's R&D Leadership Change Is End Of Bischofberger Era
Gilead's Biktarvy Approval Heightens HIV Competition With ViiV
Gilead Makes Cell Therapy The Base Of Its Oncology Platform With Kite Buy
Gilead Raises HCV Guidance Slightly, Still Mum On M&A


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts